oral semaglutide sublingual - Patients Best Oral Peptides for Weight

N = 161,798 after matching GLP-1RA vs diet/exercise consultation Median follow-up: 2 years Key result: Any obesity-associated cancer HR 0.59, 95% CI 0.53-0.67 Site-specific signals: Multiple myeloma HR 0.37 Pancreatic cancer HR 0.40 Endometrial cancer HR 0.42 Colorectal cancer HR 0.49 But remember: This is observational

And this same dynamic is playing out in healthcare markets across the country

What makes retatrutide unique is that it interacts with three different hormone receptors that play a role in appetite and energy regulation

Can GLP-1 agonists improve ovarian cancer outcomes

My take: GLP-1RAs may become more than metabolic drugs, but oncology needs prospective cancer-outcome data before calling this prevention

Explore the differences between Ozempic vs